CeriBell (NASDAQ:CBLL) Shares Gap Up – Time to Buy?

06 Oct 2026, 15:21 by Mitch Edgeman · The Markets Daily

CeriBell, Inc. (NASDAQ:CBLL – Get Free Report) gapped up prior to trading on Tuesday. The stock had previously closed at $23.69, but opened at $24.95. CeriBell shares last traded at $24.7050, with a volume of 10,850 shares traded.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. TD Cowen boosted their price objective on shares of CeriBell from $29.00 to $33.00 and gave the company a “buy” rating in a research report on Friday. Raymond James Financial reiterated a “strong-buy” rating and set a $29.00 target price on shares of CeriBell in a report on Thursday, September 3rd. Barclays raised shares of CeriBell to a “neutral” rating in a research report on Tuesday, August 18th. Canaccord Genuity Group upped their price target on shares of CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Finally, BTIG Research reiterated a “buy” rating and set a $30.00 price objective on shares of CeriBell in a research note on Friday, September 11th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $27.00.

Get Our Latest Analysis on CeriBell

CeriBell Price Performance

The company has a market capitalization of $938.77 million, a price-to-earnings ratio of -13.90 and a beta of 0.94. The company has a debt-to-equity ratio of 0.16, a current ratio of 9.18 and a quick ratio of 8.79. The stock has a fifty day simple moving average of $22.91 and a 200-day simple moving average of $20.28.

CeriBell (NASDAQ:CBLL – Get Free Report) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). The firm had revenue of $28.10 million during the quarter, compared to analysts’ expectations of $27.28 million. CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. On average, equities research analysts anticipate that CeriBell, Inc. will post -1.96 EPS for the current year.

Insiders Place Their Bets

In other news, VP David Foehr sold 9,255 shares of CeriBell stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $24.25, for a total value of $224,433.75. Following the sale, the vice president directly owned 34,144 shares of the company’s stock, valued at $827,992. The trade was a 21.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Scott Blumberg sold 1,521 shares of the company’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $24.02, for a total transaction of $36,534.42. Following the sale, the chief financial officer directly owned 146,600 shares of the company’s stock, valued at $3,521,332. The trade was a 1.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 174,905 shares of company stock valued at $4,312,995. 17.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On CeriBell

A number of institutional investors have recently made changes to their positions in CBLL. Squarepoint Ops LLC acquired a new position in CeriBell in the 2nd quarter valued at about $638,000. Wellington Management Group LLP increased its position in shares of CeriBell by 5.5% during the second quarter. Wellington Management Group LLP now owns 87,698 shares of the company’s stock worth $1,706,000 after purchasing an additional 4,572 shares in the last quarter. Formula Growth Ltd. purchased a new stake in CeriBell in the 2nd quarter valued at $603,000. Bank of America Corp DE purchased a new stake in CeriBell during the 2nd quarter valued at approximately $4,619,000. Finally, PDT Partners LLC acquired a new stake in shares of CeriBell in the 2nd quarter worth $1,026,000.

CeriBell Company Profile

(Get Free Report)

CeriBell, Inc develops medical technology designed to make electroencephalography (EEG) more accessible in acute-care settings. Its primary product is the Ceribell Rapid Response EEG system, a portable, point-of-care platform that enables clinicians to record and assess brain activity at the bedside, including when evaluating patients for seizures and status epilepticus.